Fortress Biotech, Inc. (NASDAQ:FBIOP) Sees Large Decrease in Short Interest

Fortress Biotech, Inc. (NASDAQ:FBIOP) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 200 shares, a decrease of 90.9% from the September 30th total of 2,200 shares. Based on an average daily trading volume, of 20,600 shares, the short-interest ratio is presently 0.0 days.

Fortress Biotech Stock Up 0.2 %

Fortress Biotech stock traded up $0.01 during midday trading on Friday, hitting $5.76. The stock had a trading volume of 3,713 shares, compared to its average volume of 16,706. The business has a fifty day moving average price of $5.76 and a 200 day moving average price of $10.70. Fortress Biotech has a 12 month low of $4.86 and a 12 month high of $18.00.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.